Exploring Differential Gene Expression and Biomarker Potential in Systemic Lupus Erythematosus: A Retrospective Study

This retrospective study involving 45 SLE patients and 40 healthy controls identified FCER1A and RGS1 as potential biomarkers for systemic lupus erythematosus (SLE) through integrative bioinformatics analysis and clinical validation. FCER1A was found to be significantly downregulated, while RGS1 was upregulated in SLE patients, with consistent expression trends across multiple datasets and clinical samples. These genes are involved in immune regulation, cell-mediated cytotoxicity, and apoptosis, which are crucial in SLE pathogenesis. The study also noted significant differences in lymphocyte count, red blood cell count, hemoglobin levels, and hematocrit between SLE patients and healthy controls, suggesting these as potential diagnostic markers. The findings highlight the potential of FCER1A and RGS1 for improving SLE diagnosis and as targets for future therapies, although further research is needed to understand their roles in disease progression.